Get the Stockscreener App
0.4285
2.17%
-0.0095
After Hours:
.42
-0.0085
-1.98%
Werewolf Therapeutics Inc stock is traded at $0.4285, with a volume of 385.21K.
It is down -2.17% in the last 24 hours and down -52.64% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
See More
Previous Close:
$0.438
Open:
$0.43
24h Volume:
385.21K
Relative Volume:
0.85
Market Cap:
$20.70M
Revenue:
$1.14M
Net Income/Loss:
$-60.82M
P/E Ratio:
-0.3213
EPS:
-1.3338
Net Cash Flow:
$-60.29M
1W Performance:
-21.03%
1M Performance:
-52.64%
6M Performance:
-50.93%
1Y Performance:
-60.32%
1-Day Range:
$0.404
$0.45
1-Week Range:
$0.404
$0.55
52-Week Range:
$0.404
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
0.4259 | 21.29M | 1.14M | -60.82M | -60.29M | -1.3338 |
VRTX
Vertex Pharmaceuticals Inc
|
433.59 | 109.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
642.46 | 68.12B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.23 | 50.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.57 | 39.85B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.81 | 31.96B | 742.00K | -1.37B | -1.07B | -7.0731 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Werewolf Therapeutics director Luke Evnin sells $76,363 in stock - Investing.com
Evnin-linked funds sell 171K Werewolf Therapeutics (HOWL) shares - Stock Titan
[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan
Werewolf Therapeutics Stock Rises Over 5% After Hours On Workforce Reduction, Including Executives - Stocktwits
Werewolf Therapeutics (HOWL) Stock: Down -3.84%, Support Test at $0.47 2026-05-18ATR Levels - Newser
Werewolf Therapeutics (HOWL) price target increased by 12.00% to 7.14 - MSN
Werewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38 - MSN
Werewolf Therapeutics (HOWL) Reports Strong Q4 2025 — Revenue $N/A, EPS BeatsCommunity Watchlist - Newser
RA Capital funds sell HOWL shares, report 12.6% Werewolf Therapeutics stake - Stock Titan
News | Struggling Boston biotech firm cuts ties with headquarters space - CoStar
Werewolf Therapeutics Insider Sold Shares Worth $280,210, According to a Recent SEC Filing - Moomoo
Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation - Yahoo Finance
HOWL Director Luke Evnin Sells 44,679 Shares on May 13, 2026 - Meyka
Werewolf Therapeutics director Luke Evnin sells $24,126 in stock - Investing.com UK
Werewolf Therapeutics director Luke Evnin sells $24,126 in stock By Investing.com - Investing.com Australia
Evnin-linked funds sell 44,679 Werewolf (NASDAQ: HOWL) shares under plan - Stock Titan
Werewolf Therapeutics vacates Watertown headquarters as cash dwindles - The Business Journals
TradingKey - TradingKey
Werewolf Therapeutics director Luke Evnin sells $280,210 in company stock By Investing.com - Investing.com South Africa
Werewolf Therapeutics director Luke Evnin sells $280,210 in company stock - Investing.com India
MPM group cuts Werewolf Therapeutics (HOWL) holdings in May stock sales - Stock Titan
Director-linked MPM funds trim Werewolf Therapeutics (HOWL) stake under 10b5-1 plan - Stock Titan
Ra capital, Peter Kolchinsky sell $390k Werewolf Therapeutics shares - Investing.com India
Ra capital, Peter Kolchinsky sell $390k Werewolf Therapeutics shares By Investing.com - Investing.com South Africa
RA Capital funds trim Werewolf Therapeutics (NASDAQ: HOWL) stake with 565K-share sale - Stock Titan
HOWL SEC FilingsWerewolf Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
B of A Securities Maintains Werewolf Therapeutics (HOWL) Buy Recommendation - MSN
Werewolf sells JZP898 rights to Jazz, repays K2 debt amid review - Stock Titan
Werewolf Therapeutics (NASDAQ:HOWL) Meets Q1 Estimates, Clears Debt, and Advances Strategic Review - ChartMill
Werewolf Therapeutics director Luke Evnin sells $64,216 in shares - Investing.com UK
Werewolf Therapeutics director Luke Evnin sells $64,216 in shares By Investing.com - Investing.com Nigeria
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates - Investing News Network
Funds tied to Werewolf Therapeutics (HOWL) director sell 100,581 shares - Stock Titan
Werewolf Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Strategic review, Jazz asset sale and Q1 loss at Werewolf Therapeutics (NASDAQ: HOWL) - Stock Titan
[10-Q] Werewolf Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Werewolf Therapeutics (ticker: HOWL) holders detail stake and sales in 13D/A - Stock Titan
How Werewolf Therapeutics (HOWL) earnings power compares to its price (Mini Selloff) 2026-05-05Hot Momentum Watchlist - Newser
Werewolf Therapeutics director Luke Evnin sells $198,309 in shares - Investing.com
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Werewolf Therapeutics Inc Stock (HOWL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EVNIN LUKE | Director |
May 19 '26 |
Sale |
0.45 |
62,970 |
28,336 |
1,041,342 |
| EVNIN LUKE | Director |
May 18 '26 |
Sale |
0.50 |
22,184 |
11,092 |
1,104,312 |
4.94%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):